Table 1.

Overview of cancer types and studies participating in the original meta-analyses

Cancer siteStudiesGenotyping platformsSubtypeCovariatesStudies (N)Cases (N)N controls
ColorectalAffymetrix AxiomAllAge, sex, PCs65,1004831
 MECC, CFRa, KY, ACS, Australia, NF
BreastIllumina arrays (317K-1.2M)AllAge, PCs (vary by studies)1115,56918204
 ABCFS, HEBCS, UK2, SASBAC, MARIE, CPSII, EPIC, MEC, NHS2, PBCS, PLCOESR1 (ER)-negativeAge, PCs (vary by studies)84,76013248
LungIllumina arrays (317K-610K)AllAge, sex, PCs612,52717285
 UK, MDACC, IARC, NCI, SLRI, HGFAdenocarcinomaAge, sex, PCs63,80416289
Squamous cellAge, sex, PCs63,54616434
OvaryIllumina arrays (317K-2.5M)AllStudy, PCs34,3689123
 UKGWAS, USGWAS, U19GWASEndometrioidStudy, PCs32,5539123
SerousStudy, PCs37159123
Clear cellStudy, PCs33559123
ProstateIllumina and Affymetrix arraysAllAge, study614,16012712
 BPC3, CRUK1, CRUK2, CAPSAggressive subtypeAge, study, PCs64,44612724
  • Abbreviations: ER, estrogen receptor; PCs, principal components representing residual European ancestry.

  • aColon-CFR: 1,660 cases, 1,393 controls.